ArticleFrontiers in medicine2022

The Efficacy and Safety of Pirfenidone Combined With Immunosuppressant Therapy in Connective Tissue Disease-Associated Interstitial Lung Disease: A 24-Week Prospective Controlled Cohort Study.

Jiaqi Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.